Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL19025646 | 0.92 | KDM4E (0.50) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| Thiosalicylic Acid SCHEMBL28932205 | 0.90 | MAPT (0.36) | ALDH1A1KDM4EHPGD | |
| Phthalic Acid SCHEMBL29142344 | 0.87 | ALDH1A1 (0.39) | ALDH1A1KMT2A | |
| Benzoic Acid SCHEMBL2523034 | 0.87 | CA2 (0.46) | ALDH1A1MEN1RECQLKMT2ATSHR | |
| Phthalic Acid SCHEMBL25403187 | 0.86 | ALDH1A1 (0.44) | ALDH1A1KMT2A | |
| Phthalic Acid SCHEMBL25403191 | 0.86 | ALDH1A1 (0.44) | ALDH1A1KMT2A | |
| Bicarbonate SCHEMBL2936301 | 0.84 | MEN1 (0.35) | MEN1KMT2A | |
| Acetic Acid SCHEMBL302142 | 0.82 | MEN1 (0.37) | MEN1KMT2A | |
| Bicarbonate SCHEMBL357950 | 0.82 | MEN1 (0.34) | MEN1KMT2A | |
| Bicarbonate SCHEMBL2229450 | 0.82 | MEN1 (0.34) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250174409-A1 | SOLID ELECTROLYTE CAPACITOR AND METHOD FOR MANUFACTURING SAME | CARLIT CO., LTD. (JP) | 2025-05-29 | — | — | US | disclosed |
| CN-118843914-A | Solid electrolytic capacitor and method for manufacturing the same | 佳里多股份公司 | 2024-10-25 | — | — | CN | disclosed |
| WO-2020059434-A1 | EPOXY RESIN COMPOSITION | サンアプロ株式会社 | 2020-03-26 | — | — | WO | disclosed |
| US-9959977-B2 | Electrolysis solution for electrolytic capacitor, and electrolytic capacitor | CARLIT HOLDINGS CO., LTD. (JP) | 2018-05-01 | — | — | US | disclosed |
| US-20170110253-A1 | Electrolyte Solution for Aluminum Electrolytic Capacitor and Aluminum Electrolytic Capacitor Using the Electrolyte Solution | SHENZHEN CAPCHEM TECHNOLOGY CO., LTD. (CN) | 2017-04-20 | — | — | US | disclosed |
| US-20160148756-A1 | ELECTROLYSIS SOLUTION FOR ELECTROLYTIC CAPACITOR, AND ELECTROLYTIC CAPACITOR | CARLIT CO., LTD. (JP) | 2016-05-26 | — | — | US | disclosed |
| US-8273263-B2 | Ionic compound | NICHICON CORPORATION (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2048131-A1 | IONIC COMPOUND | Nichicon Corporation (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20080083626-A1 | IONIC COMPOUND | NICHICON CORPORATION (JP) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080083626-A1 | IONIC COMPOUND | KCNN4, HCN2, CLCN2 | ALDH1A1 3642/4885KDM4E 2830/4885HPGD 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.